On May 14, 2025, Elevance Health, Inc. (NYSE: ELV) held its Annual Meeting of Shareholders with decisive outcomes on key governance and compensation matters, positioning the company for strategic continuity and robust growth. This report synthesizes the key voting results and places them in context with Elevance Health’s recent financial performance and strategic initiatives.
The shareholders elected the following nominees to serve three-year terms ending in 2028: - Susan D. DeVore: 185.8 million votes for, 3.7 million against - Bahija Jallal: 180.8 million votes for, 8.7 million against - Ryan M. Schneider: 184.6 million votes for, 5.0 million against
This strong endorsement reflects solid investor confidence in the company’s leadership.
The advisory vote approving the compensation of named executive officers received 173.9 million votes in favor versus 15.5 million against. The approval indicates shareholder support for the company’s executive remuneration policies aligned with its performance and strategic objectives.
The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was ratified with 178.1 million votes for, confirming the continuity of rigorous financial oversight.
A shareholder proposal requesting a report on the effectiveness of DEI efforts was rejected decisively with 160.7 million votes against and just 26.2 million in favor. While the proposal was not approved, Elevance Health has demonstrated substantial commitment to health equity initiatives in recent years, notably receiving the National Committee for Quality Assurance’s three-year health equity accreditation for nearly 90% of its Medicaid membership as of 2022.
For the fiscal year ending December 31, 2024, Elevance Health reported total revenues of \(176.81 billion and net income of \)5.98 billion. This translates to strong profitability amidst a complex healthcare landscape marked by regulatory changes and membership plan adjustments.
Elevance Health continues to invest heavily in growth areas such as specialty pharmacy through the acquisition of BioPlus, enhancing its pharmacy services segment “CarelonRx”, and boosting its capability to manage complex chronic conditions. With Carelon’s reported $41 billion revenue in 2022 and progression toward managing 20% of consolidated benefit expenses ahead of schedule, the company is scaling its healthcare services significantly.
The company also addresses evolving market dynamics by refining bid strategies in the Medicare Advantage business and expanding digital health tools accessibility for Medicaid members. Their innovative approach to incorporating technology and personalized customer service models like My Health Advocate is expected to improve healthcare navigation and star quality ratings.
Elevance Health projects adjusted diluted earnings per share exceeding $37.10 for 2025, representing a growth rate of at least 12% over 2024, reflecting confidence in sustained earnings growth and operational resilience.
Elevance Health’s 2025 Annual Meeting outcomes reaffirm its leadership team and auditor, while shareholder perspectives on executive pay and DEI reports reflect active engagement. Financially robust with strategic agility, the company is well-positioned to leverage its health benefits and healthcare services segments for long-term shareholder value.
For investors and industry watchers, these developments highlight Elevance Health’s commitment to health equity, sustainable growth, and operational excellence.
Source document: Elevance Health 8-K May 14, 2025